BridgeBio Oncology Therapeutics, Inc. (BBOT) Financial Statements
$2.66NASDAQ: BBOTMarket Cap $213.26M
BridgeBio Oncology Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $134.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
BridgeBio Oncology Therapeutics, Inc.: net profit was positive in 0 of 5 reported years; the most recent year shows a net loss of $134.0M.
Income Statement — 5 Years (USD millions)
Metric
2021
2022
2023
2024
2025
Revenue
$0
$0
$0
$0
$0
Operating Expenses
$0
$0
$65.0M
$81.0M
$146.0M
Operating Profit
$0
$0
$-65.0M
$-81.0M
$-146.0M
Operating Margin
0.0%
0.0%
0.0%
0.0%
0.0%
Other Income
$0
$0
$0
$7.0M
$12.0M
Interest
$0
$0
$0
$0
$0
Depreciation
$0
$0
$0
$0
$1.0M
Profit Before Tax
$0
$0
$-65.0M
$-74.0M
$-134.0M
Tax
$0
$0
$0
$0
$0
Net Profit
$0
$0
$-65.0M
$-74.0M
$-134.0M
EPS
$0.00
$0.00
$-3.16
$-5756.41
$-4.30
Dividend Payout
0.0%
0.0%
0.0%
0.0%
0.0%
Quarterly Results — Last 12 Quarters (USD millions)
Metric
Dec '22
Dec '23
Mar '24
Jun '24
Sep '24
Dec '24
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Operating Expenses
$0
$0
$15.0M
$24.0M
$20.0M
$22.0M
$23.0M
$30.0M
$49.0M
$43.0M
$46.0M
$60.0M
Operating Profit
$0
$0
$-15.0M
$-24.0M
$-20.0M
$-22.0M
$-23.0M
$-30.0M
$-49.0M
$-43.0M
$-46.0M
$-60.0M
Operating Margin
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Interest
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Profit Before Tax
$0
$0
$-15.0M
$-22.0M
$-17.0M
$-20.0M
$-22.0M
$-28.0M
$-45.0M
$-39.0M
$-42.0M
$-56.0M
Tax
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net Profit
$0
$0
$-15.0M
$-22.0M
$-17.0M
$-20.0M
$-22.0M
$-28.0M
$-45.0M
$-39.0M
$-42.0M
$-56.0M
EPS
$0.00
$0.00
$0.05
$0.09
$-0.74
$-1075.56
$-0.94
$-1.21
$-1.90
$-1.25
$-1.35
$-705.20
Over the 5 years reported for BridgeBio Oncology Therapeutics, Inc., cash stood at $374.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 12.14 times.
Balance Sheet — 5 Years (USD millions)
Metric
2021
2022
2023
2024
2025
Total Assets
$0
$0
$0
$194.0M
$448.0M
Current Assets
$0
$0
$0
$2.0M
$425.0M
Cash
$0
$0
$0
$2.0M
$374.0M
Inventory
$0
$0
$0
$0
$0
Receivables
$0
$0
$0
$0
$0
Fixed Assets
$0
$0
$0
$0
$0
Capital Work in Progress
$0
$0
$0
$0
$0
Investments
$0
$0
$0
$192.0M
$52.0M
Other Assets
$0
$0
$0
$0
$0
Total Liabilities
$0
$0
$0
$6.0M
$37.0M
Current Liabilities
$0
$0
$0
$0
$35.0M
Borrowings
$0
$0
$0
$0
$3.0M
Other Liabilities
$0
$0
$0
$6.0M
$35.0M
Equity
$0
$0
$0
$192.0M
$0
Reserves
$0
$0
$0
$189.0M
$411.0M
For BridgeBio Oncology Therapeutics, Inc., operating cash flow was positive in 0 of 5 reported years; free cash flow in the latest year was negative at $114.0M; free cash flow was positive in 0 of 5 years; financing activities used $12.0M in the latest year, which covers debt repayment, dividends and buybacks.
Cash Flow Statement — 5 Years (USD millions)
Metric
2021
2022
2023
2024
2025
Operating Cash Flow
$0
$0
$-52.0M
$-1.0M
$-114.0M
Investing Cash Flow
$0
$0
$-3.0M
$-184.0M
$73.0M
Financing Cash Flow
$0
$0
$0
$-1.0M
$-12.0M
Net Cash Flow
$0
$0
$0
$2.0M
$343.0M
Free Cash Flow
$0
$0
$-52.0M
$-1.0M
$-114.0M
Valuation & Return Ratios
Metric
Value
PEG Ratio
0.00
EV / EBITDA
-1.34
FCF Yield
-62.20%
Quick Ratio
4.69
Interest Coverage
—
Return 1Y
-18.43%
Return 3Y
—
Return 5Y
—
BridgeBio Oncology Therapeutics, Inc. (BBOT) financials — frequently asked questions
What is BridgeBio Oncology Therapeutics, Inc.'s annual revenue?
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported annual revenue of $0 in its most recent fiscal year.
What is BridgeBio Oncology Therapeutics, Inc.'s net profit?
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported a net loss of $134.0M in its most recent fiscal year.
What is BBOT EV/EBITDA?
BridgeBio Oncology Therapeutics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -1.34. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.